Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer
Phase PHASE2
Enrollment 30
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Talazoparib — Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called "poly (ADP-ribose) polymerases" also called "PARPs". PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells.

Primary Outcomes

  • Median Progression Free Survival (From the start of treatment until death or disease progression, up to approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-11-18
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Pfizer
Principal Investigators:
  • Neelima Vidula, MD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Neelima Vidula, MD
617-724-4000
nvidula@mgh.harvard.edu
Hope Rugo, MD
415-353-7070
hope.rugo@ucsf.edu
UCSF Medical Center-Mission Bay/Benioff Children's Hospital
Hope Rugo, MD
UCSF Medical Center-Mission Bay/Benioff Children's Hospital
Interventions
  • Drug: Talazoparib — Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called "poly (ADP-ribose) polymerases" also called "PARPs". PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells.
Study Locations (7 sites)
UCSF Medical Center-Mission Bay/Benioff Children's Hospital, San Francisco, California 94143 United States
Emory University Winship Cancer Institute, Atlanta, Georgia 30322 United States
Northwestern University, Chicago, Illinois 60611 United States
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114 United States
Weill Cornell Medicine, New York, New York 10065 United States
Vanderbilt University, Nashville, Tennessee 37232-6307 United States
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Metastatic breast cancer with deleterious somatic BRCA 1 or 2 mutations detectable by cell-free circulating tumor DNA, by CLIA certified clinical assay (including but not restricted to MGH-Snapshot cfDNA assay, Guardant360, Foundation One). The eligibility of a given assay and/or BRCA mutation could be discussed with the primary investigator (Dr. Vidula) and senior investigator (Dr. Bardia), who will provide the final discretion. * Patients with germline BRCA 1 or 2 mutations will not be eligible. * Patients with only a VUS (Variant of Unknown Significance), or non-functional BRCA mutation, without a deleterious somatic BRCA 1 or 2 mutation will not be eligible. * The following disease subtypes are eligible: * Triple negative breast cancer (defined as ER \< 1%, PR \< 1%, HER2 negative, as per ASCO CAP guidelines), with disease progression on at least one prior chemotherapy regimen in the metastatic setting. * Hormone receptor positive, HER2 negative disease with disease progression on at least one prior endocrine therapy in the metastatic setting or be considered inappropriate for endocrine therapy * Patients must have evaluable or measurable disease. * Any number of prior lines of therapy are allowed * Patients may have received prior platinum based chemotherapy (0-1 prior platinum based therapy). However, the patient must not have progressed while on platinum treatment (any setting), or within 6 months after end of treatment (neoadjuvant and/or adjuvant). * At least two weeks from last systemic therapy for breast cancer, with recovery of all treatment related toxicity to grade 1 or less. Subjects with ≤ Grade 2 neuropathy are an exception to this criterion. * At least two weeks from last radiation therapy, with recovery of all treatment related toxicity to grade 1 or less. -≥ 18 years of age on day of signing informed consent. * ECOG performance status of ≤2. * Adequate organ function as defined in Table 1 within 10 days prior to treatment initiation. * Adequate Organ Function Laboratory Values * SYSTEM LABORATORY VALUE * Hematological * Absolute neutrophil count (ANC) ≥1,500 /mcL * Platelets ≥100,000 / mcL * Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment) * Renal --Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X institutional upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels \> 1.5 X institutional ULN * Hepatic * Serum total bilirubin ≤ 1.5 X institutional ULN OR Direct bilirubin ≤ institutional ULN for subjects with total bilirubin levels \> 1.5 ULN * AST (SGOT) and ALT (SGPT) ≤ 2.5 X institutional ULN OR ≤ 5 X institutional ULN for subjects with liver metastases * Prior CNS disease is allowed if stable for at least one month since whole brain radiation therapy in patients who received whole brain radiation, or 2 weeks since stereotactic radiotherapy in patients who received stereotactic radiotherapy. Patients should not be requiring steroids. Patients whose CNS disease was surgically treated may be enrolled if stable for at least one month after surgery, and not requiring steroids. * Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. * Female subjects of childbearing potential must use an acceptable form of birth control per treating physician discretion or be surgically sterile, or abstain from heterosexual activity for the course of the study through 7 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year. * Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy. Additionally, male patients may not donate sperm during the duration of the study and through 7 months after the last dose of study therapy. * Willing and able to provide written informed consent. Exclusion Criteria: * Treatment with an investigational agent within 4 weeks of the first dose of treatment. * Patients must not have received prior treatment with a PARP inhibitor * Patients must not have a germline BRCA 1 or 2 mutation * Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion. --If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. * Has known, untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 7 months after the last dose of trial treatment. * Has a known history of Human Immunodeficiency Virus (HIV). * Has known active Hepatitis B or Hepatitis C. * Patients should not be on strong P-glycoprotein inhibitors. * Patients should not be on any other anti-cancer therapy (chemotherapy, hormone therapy, immunotherapy, or alternate investigational therapy).
Conditions CIPN - Chemotherapy-Induced Peripheral N...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Due to well-proven survival benefit, paclitaxel and other taxane-based chemotherapies are first-line agents for both the adjuvant and neoadjuvant treatment of early stage breast cancer. Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and disabling side effect of taxane anticancer agents. No established strategy exists for CIPN prevention. This study is designed to assess the efficacy and safety of cryotherapy for the prevention of paclitaxel-induced peripheral neuropathy in patients with breast cancer in a prospective randomized controlled trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA — Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).

Primary Outcomes

  • Incidence of peripheral neuropathy (CIPN is assessed 21 days after last completed cycle of paclitaxel and compared to baseline.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-01-15
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maria Lendorf
Collaborators: Danish Cancer Society, Aarhus University Hospital, Nordsjaellands Hospital, Hospital of Southern Jutland
Contact Information
Study Contact:
Maria E Lendorf, MD, PhD
+4526270898
maria.elisabeth.lendorf.02@regionh.dk
Maria E Lendorf
+4526270898
maria.elisabeth.lendorf.02@regionh.dk
Maria E Lendorf
Interventions
  • Device: Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA — Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
Study Locations (1 sites)
Maria E Lendorf, Copenhagen, 2100 Denmark
Eligibility Criteria
Inclusion Criteria: Key inclusion criteria; Patients with early breast cancer scheduled to receive weekly paclitaxel (80mg/m2 for one hour) 9 or 12 doses, PS 0-1 Exclusion Criteria: Peripheral sensory/motor neuropathy, neuralgia or edema of the limb graded \>=2 (CTCAE ver 5.0), Patient with Raynaud's symptoms; peripheral arterial ischemia; or any other reasons based on the primary physician's judgment.

UCF MammoChat: Image Repository

NCT07214883
Recruiting
Conditions Breast Cancer, Breast Cancer Awareness, ...
Phase Not Applicable
Enrollment 20000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to develop AI models to better read diagnostic mammograms for various populations and types of breast cancer, using the images that participants donate and their responses from study questionnaire to improve patient outcomes. This study also aims to provide mammography images to participants.

Design

Study type: Observational Observational model: Case Only Time perspective: Other

Interventions / Regimen

  • Other: No Interventions — No intervention for participants.

Primary Outcomes

  • AI model training using mammograms (1 year)
  • Provide mammography images to participants (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-03
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Central Florida
Collaborators: Florida Department of Health
Principal Investigators:
  • Jane Gibson, PhD (PRINCIPAL_INVESTIGATOR) - University of Central Florida
Contact Information
Study Contact:
Amoy Fraser, PhD, CCRP, PMP
4072668742
Amoy.Fraser@ucf.edu
Britney-Ann Wray, BS, CTBS, CCRP
4072668742
britney-ann.wray@ucf.edu
Amoy Fraser, PhD, CCRP, PMP
4072668742
britney-ann.wray@ucf.edu
University of Central Florida
Interventions
  • Other: No Interventions — No intervention for participants.
Study Locations (1 sites)
University of Central Florida, Orlando, Florida 32827 United States
Eligibility Criteria
Inclusion Criteria: * Adults, ages 18 and older * Had a radiographic breast cancer imaging test, either for screening or diagnosis of breast cancer, with either positive or negative results performed in a US institution. * Have an email account with access to a reliable internet connection or smartphone * Pregnant women may choose to participate. Exclusion Criteria: * Minors , ages under 18 * Prisoners * Adults who are unable to provide consent.
Conditions Breast Cancer
Phase PHASE3
Enrollment 312
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative recurrent or metastatic breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: JS105 — Patients will receive oral JS105 on Days 1-28 of each 4-week cycle.
  • Drug: Dalpiciclib — Patients will receive oral Dalpiciclib for 3 weeks, followed by 1 week off in each 4-week cycle;
  • Drug: Fulvestrant 50 Mg/mL Intramuscular Solution — Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then on day 1 of each subsequent 4-week cycle.

Primary Outcomes

  • Blind Independent Central Review (BICR) assessed PFS based on RECIST v1.1 (BICR-PFS) (Up to 3.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-11-12
Completion: 2030-05-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 312 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.
Principal Investigators:
  • Xianming Luo, Doctor (STUDY_DIRECTOR) - Medical Director
Contact Information
Study Contact:
Qianna Zhan, Master
13526615319
zhan@junshipharma.com
Huiyu Lan, Master
15000239047
huiyu_lan@junshipharma.com
Min Yan, Ph.D
0371-65588404
ym200678@126.com
Chinese Acadamy of Medical Sciences and Peking Union Medical College
Interventions
  • Drug: JS105 — Patients will receive oral JS105 on Days 1-28 of each 4-week cycle.
  • Drug: Dalpiciclib — Patients will receive oral Dalpiciclib for 3 weeks, followed by 1 week off in each 4-week cycle;
  • Drug: Fulvestrant 50 Mg/mL Intramuscular Solution — Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then on day 1 of each subsequent 4-week cycle.
Study Locations (2 sites)
Chinese Acadamy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality 100021 China
Henan Provincial Cancer Hospital, Zhengzhou, Henan 450003 China
Eligibility Criteria
Inclusion Criteria: 1. At the time of signing the consent form, age must be between 18 and 75 years old, males and females; 2. Patients with unresectable PIK3CA-mutated HR-positive HER2-negative recurrent or metastatic breast cancer; 3. Consent to provide tumour tissue or blood samples to determine the PIK3CA mutation status; 4. ECOG 0 or 1; 5. At least one measurable lesion as per RECIST v1.1, or only bone metastases; 6. Expected survival≥12 weeks; 7. Good organ function; 8. Patients voluntarily join the study and sign the informed consent; Exclusion Criteria: 1. Previously treated with fulvestrant or PI3K/AKT/mTOR inhibitors; 2. Presence of untreated or active central nervous system (CNS) metastases; 3. Presence of significant clinical symptoms or uncontrolled pleural effusion, ascites, or pericardial effusion that require repeated drainage (once a month or more frequently); 4. Untreated spinal cord compression, or previously treated spinal cord compression without clinical evidence of disease stability for at least 4 weeks prior to the first study treatment; 5. Have received other anti-tumor treatment within 2-4 weeks before the first dose; 6. Toxicities from prior anti-tumor therapy that have not recovered to ≤ Grade 1; 7. Coexisting uncontrolled accompanying diseases, including but not limited to: history of type I diabetes or uncontrolled type II diabetes, presence of active infection, severe cardiovascular or cerebrovascular diseases, etc; 8. Having another malignant tumour within the last 5 years prior to the first study treatment, except for malignancies that are expected to be cured after treatment; 9. Active hepatitis B or C; 10. Known hypersensitivity to any of the study drugs or their excipients; 11. Pregnant or breastfeeding females; 12. Presence of other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participation in the study, affect treatment compliance, or interfere with study results, as judged by the investigator;
Conditions Triple Negative Breast Neoplasms, Triple...
Phase PHASE2
Enrollment 23
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II, single-arm, open label study to evaluate Olaparib plus Pembrolizumab following platinum-based chemotherapy plus Pembrolizumab as neoadjuvant therapy for germline BRCA (gBRCA) 1/2 mutated triple negative breast cancer (TNBC). Pembrolizumab in combination with weekly paclitaxel and carboplatin (treatment 1) is followed by Pembrolizumab in combination with Olaparib (treatment 2) in neoadjuvant setting and Pembrolizumab in combination with Olaparib in adjuvant setting will be studied

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pembrolizumab — 200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
  • Drug: Paclitaxel — 80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
  • Drug: Carboplatin — Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
  • Drug: Olaparib — 300 mg BID (twice daily) orally
  • Procedure: Definitive Surgery — Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.

Primary Outcomes

  • Pathological Complete Response (pCR) Rate (ypT0/TisypN0) (From 27 weeks up to 30 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-16
Completion: 2028-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 23 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Okayama University
Collaborators: Merck Sharp & Dohme LLC
Principal Investigators:
  • Yuko Takahashi, MD., PhD. (PRINCIPAL_INVESTIGATOR) - Assistant Professor, Endocrinological Center, Okayama University Hospital
Contact Information
Study Contact:
Yuko Takahashi, MD., PhD.
+81-86-223-7151
yukotaka@okayama-u.ac.jp
Hironobu TAN, PhD.
+81-86-235-7994
hironobu_tan@okayama-u.ac.jp
Manabu Futamura, MD., PhD.
+81-58-230-6000
Gifu University Hospital
Interventions
  • Drug: Pembrolizumab — 200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
  • Drug: Paclitaxel — 80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
  • Drug: Carboplatin — Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
  • Drug: Olaparib — 300 mg BID (twice daily) orally
  • Procedure: Definitive Surgery — Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
Study Locations (3 sites)
Gifu University Hospital, Gifu, Gifu 5011194 Japan
Okayama University Hospital, Okayama, Japan
St. Luke's International Hospital, Tokyo, Japan
Eligibility Criteria
Inclusion Criteria: * Male/female subjects who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of invasive breast cancer * Have histologically confirmed TNBC, as defined by the most recent ASCO/CAP guidelines. * Confirmed germline BRCA 1/2 mutated. * Have previously untreated locally advanced non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per AJCC for breast cancer staging criteria version 7 as assessed by the investigator based on radiological and/or clinical assessment: 1. T1c, N1-N2 2. T2, N0-N2 3. T3, N0-N2 4. T4a-d, N0-N2 * It has been confirmed that there is no distant metastasis to each organ by the following tests. Chest: Contrast CT or FDG-PET/CT Abdominal: Contract CT\* or FDG-PET/CT Bone: Bone scintigraphy or FDG-PET/CT Brain: In the case of no central nervous system symptoms, examination for brain metastasis is not required. * The subject (or legally acceptable representative if applicable) provides written informed consent for the trial. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Have adequate organ function as defined in the protocol. Specimens must be collected within 10 days prior to the start of study treatment. Exclusion Criteria: * Subjects who has a positive urine pregnancy test within 72 hours prior to registration * Has diagnosed as inflammatory breast cancer. * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor . * Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. * Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * Has severe hypersensitivity (≥Grade 3) to pembrolizumab and investigational drugs used in this study and/or any of their excipients. * Has active autoimmune disease that has required systemic treatment in the past 2 years * Has a history of (non-infectious) pneumonitis/interstitial lung disease . * Has an active infection requiring systemic therapy. * Has a known history of Human Immunodeficiency Virus (HIV) infection. * Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HbsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. * Has a known history of active TB (Bacillus Tuberculosis). * Has a history or current evidence of any condition, therapy, or laboratory abnormality. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Is pregnant or breastfeeding, or expecting to conceive or father children. * Has had an allogenic tissue/solid organ transplant. * Has received pre-treatment with Olaparib or other PARP inhibitors. * Has significant cardiovascular disease * Has a resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions. * Subject has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML. * Subject received colony-stimulating factors within 28 days prior to the first dose of study intervention. * Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. * Is either unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption. * Is, in the judgement of the investigator, unlikely to comply with the study procedures, restrictions, and requirements of the study. * Is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study. * Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study.
Conditions Breast Cancer
Phase PHASE2
Enrollment 236
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is an investigator-initiated randomized controlled, open-label, multicenter, prospective Phase 2 clinical study. Patients with stage II-III HR +/HER2 + breast cancer were randomly divided into two groups at a ratio of 1:1. The experimental group received pyrotinib combined with trastuzumab, dalpiciclib and letrozole; the control group received trastuzumab combined with pertuzumab, docetaxel and carboplatin. The main study objective was to evaluate the efficacy and safety of neoadjuvant therapy for HR +/HER2 + breast cancer in the two groups.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib — 320mg, qd
  • Drug: Trastuzumab — 8 mg/kg first dose, then 6 mg/kg,q3w
  • Drug: Dalpiciclib — 125mg , qd,d1-21, q4w
  • Drug: Letrozole — 2.5mg,qd
  • Drug: Pertuzumab — 840 mg first dose, then 420 mg, q3w
  • Drug: Docetaxel — 75 mg/m2, q3w
  • Drug: Carboplatin — AUC 6, q3w
  • Drug: Gonadotropin-releasing hormone agonist — Every 4 weeks for 5 cycles, premenopausal patients only

Primary Outcomes

  • Pathologic Complete Response Rate (tpCR: ypT0-is/ypN0) (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-12-20
Completion: 2027-12-10
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 236 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Contact Information
Study Contact:
Nan Niu
+8618940256668
niunannancy@163.com
Cai-Gang Liu, PHD
+86 18940254967
liucg@sj-hospital.org
Shengjing Hospital of China Medical University
Cai-Gang Liu, PHD
Shengjing Hospital of China Medical University
Interventions
  • Drug: Pyrotinib — 320mg, qd
  • Drug: Trastuzumab — 8 mg/kg first dose, then 6 mg/kg,q3w
  • Drug: Dalpiciclib — 125mg , qd,d1-21, q4w
  • Drug: Letrozole — 2.5mg,qd
  • Drug: Pertuzumab — 840 mg first dose, then 420 mg, q3w
Study Locations (1 sites)
Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18 -75 ; 2. Willing to receive LHRH agonist therapy (premenopausal patients only); 3. All patients were histopathologically confirmed to be estrogen receptor (ER) -positive and HER2-positive. 4. Treatment-naïve stage II-III patients with tumor stage meeting AJCC version 8 criteria; 5. ECOG score 0-1; 6. Organ function level must meet the following requirements: (1) bone marrow function • ANC ≥ 1.5 x 109/L ; • PLT ≥ 100 × 109/L • Hb ≥ 90 g/L ; (2) hepatic and renal function • TBIL ≤ 1.5 × ULN; • AL and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN in patients with liver metastases); • BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min; (Cockcroft-Gault formula) (3) Echocardiography: LVEF ≥ 50%; (4) 12-lead ECG: QT interval ≤ 480 ms; 7. Able to undergo needle biopsy; 8. Voluntarily join this study to sign informed consent, have good compliance and willing to cooperate with follow-up. Exclusion Criteria: 1. Received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.); 2. Received any other anti-tumor therapy at the same time; 3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer; 4. Stage IV breast cancer; 5. Breast cancer without histopathological diagnosis; 6. Other malignant tumors in the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ; 7. Severe heart, liver and kidney and other vital organ dysfunction; 8. Inability to swallow, chronic diarrhea and intestinal obstruction, there are a variety of factors affecting drug administration and absorption; 9. Participated in other drug clinical trials within 4 weeks before enrollment; 10. Known history of hypersensitivity to the drug components of this protocol; history of immunodeficiency, including positive HIV test, HCV, active viral hepatitis B or other acquired, congenital immunodeficiency diseases, or history of organ transplantation; 11. Had any cardiac disease, including: (1) cardiac arrhythmia requiring medication or clinically significant; (2) myocardial infarction; (3) heart failure; (4) any other cardiac disease judged by the investigator to be inappropriate for participation in this trial; 12. Female patients who are pregnant or lactating, female patients of childbearing potential with a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial; 13. According to the investigator 's judgment, there are concomitant diseases that seriously jeopardize the patient' s safety or affect the patient 's completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, etc.); 14. Had a documented history of neurological or psychiatric disorders, including epilepsy or dementia.Any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.
Conditions HER2-positive Advanced Breast Cancer
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world. The study will be conducted by signing an informed consent form for study enrollment, collecting patient case information, and conducting observation and follow-up.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Inetetamab Combined With Pyrotinib and Vinorelbine — Inetetamab Combined With Pyrotinib and Vinorelbine

Primary Outcomes

  • Progressive free survival(PFS) (From date of treatment of inetetamab combined with pyrotinib and vinorelbine until the date of the progression of the tumor or death from any cause, whichever came first, assessed up to about 48 months)
  • Adverse events (assessed up to 48 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-16
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang Cancer Hospital
Principal Investigators:
  • Chen zhanhong (PRINCIPAL_INVESTIGATOR) - Zhejiang Cancer Hospital
Contact Information
Study Contact:
Chen zhanhong
+8613606505124
czred@sina.com
Chen zhanhong
13606505124
czred@sina.com
Zhejiang Cancer Hospital
Interventions
  • Drug: Inetetamab Combined With Pyrotinib and Vinorelbine — Inetetamab Combined With Pyrotinib and Vinorelbine
Study Locations (1 sites)
Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. The HER2 positive advanced breast cancer confirmed by cytology or histology must meet the following conditions at the same time: (1) HER2 positive is defined as\>10% of immunoreactive cells with an immunohistochemical (IHC) score of 3 or an in situ hybridization (ISH) result of HER2 gene amplification (2) Advanced breast cancer is defined as locally advanced breast cancer or metastatic breast cancer that cannot be removed by radical surgery confirmed by researchers; 3. The functional level of the main organs has been evaluated by the researchers to withstand chemotherapy, anti HER2 monoclonal antibodies, and anti HER2 TKI drugs. The LVEF and QT intervals measured by echocardiography or MUGA are within a clinically acceptable safety range. If the survival benefits of the treatment value are assessed by the researcher to be greater than the risks faced, the admission conditions for the specific organ function level can be appropriately relaxed by the researcher, but the reasons need to be explained in the medical record; 4. ECOG score: 0-2 points; 5. Voluntarily sign the informed consent form for this study. 6. Contraception during the study period and within 6 months after treatment, non lactation. Exclusion Criteria: 1. Pregnant or lactating women; 2. At the same time or in the past five years, patients with one or more malignant tumors with metastatic capacity or potential other than HER2 positive breast cancer, but not including cured cervical carcinoma in situ, thyroid cancer, skin basal cell carcinoma or squamous cell carcinoma. For other malignant tumors occurring within a period of more than 5 years from this treatment, if only cured by surgery, they are allowed to be included. 3. Persons with a known history of allergy to the drug components of this protocol; 4. Have a history of immunodeficiency, including HIV testing positive, or have other acquired or congenital immunodeficiency diseases; 5. The researcher believes that it is not suitable for inclusion.
Conditions HER2-positive Breast Cancer
Phase PHASE3
Enrollment 596
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-M07D1 — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Pertuzumab — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Trastuzumab — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Docetaxel — Administration by intravenous infusion for a cycle of 3 weeks.

Primary Outcomes

  • Progression-free survival (PFS) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-04-21
Completion: 2029-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 596 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Sa Xiao, PHD
15013238943
xiaosa@baili-pharm.com
Herui Yao
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Herui Yao
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Interventions
  • Drug: BL-M07D1 — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Pertuzumab — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Trastuzumab — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Docetaxel — Administration by intravenous infusion for a cycle of 3 weeks.
Study Locations (2 sites)
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong China
West China Hospital of Sichuan University, Chengdu, Sichuan China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form and comply with the protocol requirements; 2. Female patients aged ≥18 and ≤75 years at the time of signing the informed consent form; 3. Expected survival time ≥12 weeks; 4. Patients with histologically or cytologically confirmed, previously untreated, unresectable recurrent or metastatic HER2-positive breast cancer; 5. Clear hormone receptor (HR) status; 6. Agree to provide eligible tumor tissue specimens; 7. Have at least one measurable target lesion as defined by RECIST v1.1; 8. ECOG performance status score of 0 or 1; 9. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0; 10. Organ function levels must meet the requirements; 11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with a negative serum pregnancy result, and must be non-lactating; all enrolled patients must use adequate and highly effective contraceptive measures throughout the entire treatment period and for 7 months after treatment completion. Exclusion Criteria: 1. Received surgical treatment, radical radiotherapy, immunotherapy, etc. within 4 weeks or 5 half-lives prior to the first dose. 2. Previously received ADC drug therapy with camptothecin derivatives as toxins. 3. History of severe cardiovascular or cerebrovascular disease within six months before screening. 4. Concomitant pulmonary disease resulting in severely impaired lung function. 5. History of interstitial lung disease (ILD)/interstitial pneumonia requiring corticosteroid therapy, etc. 6. QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias. 7. Diagnosed with another primary malignancy within 5 years before the first dose. 8. Newly developed deep vein thrombosis within 14 days before screening. 9. Hypertension poorly controlled by antihypertensive medications. 10. Patients with active central nervous system metastases. 11. History of severe allergic reactions to recombinant humanized antibodies or any excipient or component of BL-M07D1. 12. History of autologous or allogeneic stem cell transplantation or organ transplantation. 13. Previously received anthracycline therapy exceeding the prescribed dose limit. 14. Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection. 15. Severe infection within 4 weeks prior to the first use of the study drug, etc. 16. Patients with large serous cavity effusions, serous cavity effusions with obvious symptoms, or poorly controlled serous cavity effusions. 17. Receiving systemic corticosteroid therapy \>10 mg/day prednisone or equivalent prior to randomization, etc. 18. Presence of severe neurological or psychiatric disorders. 19. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent. 20. Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc. 21. Subjects planning to receive or having received live vaccines within 28 days before the first dose. 22. Presence of other serious physical conditions, abnormal laboratory findings, or poor compliance that may increase the risk of participating in the study, interfere with study results, or make the patient unsuitable for participation in the study in the investigator's opinion.
Conditions Metastatic HR+/HER2- Breast Cancer
Phase PHASE2
Enrollment 108
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, multicenter, phase II clinical trial evaluating prophylactic strategies to mitigate common toxicities associated with capivasertib in combination with fulvestrant in participants with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who are eligible for this treatment regimen.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Capivasertib — 400 mg orally, twice daily (BID), on 4-days-on/3-days-off schedule.
  • Drug: Loperamide — 2 mg orally once daily on capivasertib dosing days
  • Drug: Fulvestrant — 500 mg Administered intramuscularly every 14 days for the first three injections and every 28 days thereafter.
  • Drug: Ceterizine — 10 mg orally once a day, starting on Cycle 1 Day 1 and continued for the first eight weeks (each cycle=28 days)

Primary Outcomes

  • Number of patients who experience grade 2 or greater diarrhea as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (At the eight-week mark from the commencement of the capivasertib treatment in the study)
  • Number of patients who experience grade 2 or greater rash as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (At the eight-week mark from the commencement of the capivasertib treatment in the study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-08-15
Completion: 2029-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maryam Lustberg
Collaborators: AstraZeneca
Principal Investigators:
  • Maryam Lustberg, MD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Laura Kane
773-369-6904
Laura.Kane@yale.edu
Carl Brown
475-241-1065
carl.brown@yale.edu
Yale University
Maryam Lustberg, MD
Yale University
Interventions
  • Drug: Capivasertib — 400 mg orally, twice daily (BID), on 4-days-on/3-days-off schedule.
  • Drug: Loperamide — 2 mg orally once daily on capivasertib dosing days
  • Drug: Fulvestrant — 500 mg Administered intramuscularly every 14 days for the first three injections and every 28 days thereafter.
  • Drug: Ceterizine — 10 mg orally once a day, starting on Cycle 1 Day 1 and continued for the first eight weeks (each cycle=28 days)
Study Locations (1 sites)
Yale University, New Haven, Connecticut 06510 United States
Eligibility Criteria
Inclusion Criteria: 1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the clinical study protocol. 2. Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses. 3. Participants must be aged ≥18 years at the time of signing the ICF. 4. Adult females, pre- and/or post-menopausal, and adult males: \- Pre-menopausal (and peri-menopausal i.e., those that do not meet the criteria for post-menopausal defined below) women can be enrolled if amenable to treatment with an LHRH agonist. Participants are to have commenced concomitant treatment with LHRH agonist at least four weeks prior to Cycle 1, Day 1 and must be willing to continue it for the duration of the study. Post-menopausal women are defined as: * Aged ≥60 years of age, OR * Aged \<60 years of age and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments/chemotherapy/ovarian suppression/tamoxifen or similar. These participants should also have serum estradiol and follicle stimulating hormone (FSH) levels confirmed as being within the standard laboratory reference range for post-menopausal females, OR * Documented irreversible bilateral oophorectomy. 5. Metastatic or locally advanced disease with radiological or objective evidence of recurrence or progression; locally advanced disease must not be amenable to resection with curative intent. 6. Participants with metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as confirmed by local or central testing of tumor tissue and/or circulating tumor DNA (ctDNA). 7. Participants eligible for treatment with capivasertib and fulvestrant for metastatic breast cancer. 8. ECOG performance status 0 or 1 with no deterioration over the previous 2 weeks and life expectancy of ≥12 weeks. 9. Adequate hematologic, coagulation, hepatic, and renal parameters. 10. Participants must be able to swallow and retain oral medication. 11. Participants must adhere to the following reproductive and contraceptive requirements: a. For participants of childbearing potential (POCBP): i. Participant of childbearing potential is defined as an individual who is premenopausal and capable of becoming pregnant, including those using contraception, those who are single, or those with partners who have had a vasectomy. ii. Participants must not be pregnant or breastfeeding. iii. A negative serum pregnancy test must be obtained at screening within 72 hours before the first dose of the study treatment, and participants must agree to further pregnancy tests throughout the study, if required. iv. Participants must use at least one highly effective method of contraception combined with a barrier method while on study treatment and for 1 years after the last dose of the study drug. v. Participants must not donate or freeze eggs for future use related to assisted reproduction while on study treatment and for 1 month after the last dose of the study drug. b. For participants with partners of childbearing potential: i. If a participant has a partner who could become pregnant, that partner must use a highly effective method of contraception combined with a barrier method while the participant is on study treatment and for 16 weeks after the last dose of the study drug, unless the participant is vasectomized. ii. Participants must not donate or freeze sperm for future use related to assisted reproduction while on study treatment and for 4 months after the last dose of the study drug. c. Highly effective methods of contraception include: i. Combined hormonal contraception (estrogen and progestogen) that inhibits ovulation (oral, intravaginal, or transdermal). ii. Progestogen-only hormonal contraception that inhibits ovulation (oral, injectable, or implantable). iii. Intrauterine device (IUD). iv. Intrauterine hormone-releasing system. v. Bilateral tubal occlusion. vi. Sexual abstinence (the reliability of abstinence must be evaluated concerning the duration of the clinical study and the participant's lifestyle). vii. A vasectomized partner (provided the partner is the sole sexual partner of the POCBP study participant and that the vasectomized partner has received medical confirmation of the surgical success). d. Barrier methods are not considered highly effective and should not be used alone to meet study contraceptive requirements. However, they may be used in addition to a highly effective method for extra protection. These include: i. Male condom. ii. Female condom. iii. Cervical cap. iv. Diaphragm with spermicide. v. Contraceptive sponge with spermicide Exclusion Criteria: 1. A disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment (e.g., symptomatic visceral disease that is potentially life-threatening in the short-term) 2. Malignancies other than breast cancer within five years prior to study treatment initiation (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma or Stage I endometrioid uterine cancer). 3. With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment. 4. Known abnormalities in coagulation such as bleeding diathesis, or treatment anticoagulants precluding intramuscular injections of fulvestrant or LHRH, if applicable. 5. Prior exposure to any chemotherapy or anti-cancer agents other than those specified in the protocol (e.g. hormonal therapy such as LHRH agonists) without appropriate washout period before randomization/enrollment, for example, randomization within 3 half-lives of a small molecule anti-cancer agent, or within 4 weeks for any antibody-based anticancer agents. 6. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer. 7. Radiotherapy within 2 weeks prior to the first dose of study intervention 8. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. 9. Strong inhibitors of CYP3A4 or strong/moderate inducers of CYP3A4 within 2 weeks prior to the first dose of capivasertib (3 weeks for St John's wort), Note that adequate washout or dose reduction may be required for some CYP3A substrates with a narrow therapeutic window prior to initiating capivasertib dosing. 10. Any concomitant medication that may interfere with fulvestrant, cetirizine, and loperamide safety and efficacy based on the prescribing information of fulvestrant, cetirizine, and loperamide and local clinical guidelines. 11. Clinically significant abnormalities of glucose metabolism as defined by any of the following: 1. Participants with diabetes mellitus type 1 or diabetes mellitus type 2 requiring insulin treatment. 2. HbA1c ≥8.0% (63.9 mmol/mol). 12. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids within four weeks prior to study treatment initiation. 13. Leptomeningeal metastases. 14. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: 1. Absolute neutrophil count \<1.5 × 109 /L. 2. Platelet count \<100 × 109 /L. 3. Hemoglobin \<9 g/dL (\<5.59 mmol/L). NOTE: any blood transfusion must be \>14 days prior to the determination of a haemoglobin ≥9 g/dL (≥5.59 mmol/L). 4. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \>2.5 times upper limit of normal (ULN) if no demonstrable liver metastases or \>5 × ULN in the presence of liver metastases. 5. Total bilirubin \>1.5 × ULN (participants with confirmed Gilbert's syndrome may be included in the study). 6. Creatinine \>1.5 × ULN concurrent with creatinin
Conditions Breast Cancer Prevention
Phase NA
Enrollment 2080
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide, with early-onset cases increasing due to genetic and lifestyle factors. Traditional prevention strategies have shown limited effectiveness, creating the need for innovative approaches. The MELIORA project develops an AI-driven digital tool, the Virtual Coach (VC), to promote sustainable behaviour change in physical activity, diet, and alcohol use. Three randomized-controlled studies will be conducted: MELIORA-HEALTHY (women at risk, n=1080 in Greece, Lithuania, Spain), MELIORA-PATIENTS (women undergoing treatment, n=400 in Lithuania, Spain), and MELIORA-SURVIVORS (post-treatment survivors, n=600 in Lithuania, Spain, Sweden). Participants across diverse regions and backgrounds will be randomized to standard lifestyle advice or the same advice plus the MELIORA VC app. Each study lasts 12 months, with outcomes assessed at baseline, 6, and 12 months. The primary outcome is physical activity, with secondary outcomes including sedentary behaviour, diet, alcohol use, and quality of life. If effective, the MELIORA VC could offer a scalable, cost-effective model for BC prevention and survivorship care, providing valuable evidence to guide public health strategies.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: MELIORA Virtual Coach Intervention — Based on baseline assessments, the MELIORA VCI app will prompt intervention group participants to set weekly goals on lifestyle behaviours such as physical activity, diet, alcohol use, and sedentary time, and support daily self-monitoring and step count tracking. Goals will be dynamically adjusted by the virtual coach or the participant to remain realistic and achievable. Τhe app will also offer culturally adapted educational, motivational, and instructional support through mini-courses, tips, recommendations and an embedded library of relevant materials to ensure high adoption rates among women from diverse countries, socioeconomic backgrounds and minority groups. To boost motivation, it will include reminders, gamification features like badges and points, as well as personalized techniques such as action planning, problem solving, social reward, and positive self-talk.
  • Other: Control (generic advice) — The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. A 'light' version of the MELIORA VCI app will be developed to host the control group materials, track participants' step counts, send reminders, and allow scheduling of follow-up visits. No other features will be available in this version of the app.

Primary Outcomes

  • Physical activity levels - MVPA minutes (From baseline (T0) until the end of the six-month intervention period (T1))
  • Physical activity levels - Step count (From baseline (T0) until the end of the six-month intervention period (T1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 2080 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Harokopio University
Collaborators: BROSTCANCERFORENINGEN AMAZONA I STOCKHOLMS LAN, Karolinska Institutet, Instituto de Investigacion Sanitaria INCLIVA, FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA, LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS, PAGALBOS ONKOLOGINIAMS LIGONIAMS ASOCIACIJA, SWPS UNIWERSYTET HUMANISTYCZNOSPOLECZNY, EUROPEAN FOOD INFORMATION COUNCIL, PredictBy Research and Consulting, S.L, ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS, EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS, RISA SICHERHEITSANALYSEN GMBH, BioAssist, EUROPEAN HEALTH MANAGEMENT ASSOCIATION, ETICAS DATA SOCIETY
Principal Investigators:
  • Yannis Manios, Professor (PRINCIPAL_INVESTIGATOR) - Department of Nutrition and Dietetics, School of Health Science & Education, Harokopio University, Athens, Greece
Contact Information
Study Contact:
Yannis Manios, Professor
+30 2109549156
manios@hua.gr
Yannis Manios, Professor
+302109549156
manios@hua.gr
Harokopio University
Gintare Kaliniene
+370868409708
gintare.kaliniene@lsmu.lt
Lietuvos Sveikatos Mokslų Universitetas (Lsmu)
Interventions
  • Behavioral: MELIORA Virtual Coach Intervention — Based on baseline assessments, the MELIORA VCI app will prompt intervention group participants to set weekly goals on lifestyle behaviours such as physical activity, diet, alcohol use, and sedentary time, and support daily self-monitoring and step count tracking. Goals will be dynamically adjusted by the virtual coach or the participant to remain realistic and achievable. Τhe app will also offer culturally adapted educational, motivational, and instructional support through mini-courses, tips, recommendations and an embedded library of relevant materials to ensure high adoption rates among women from diverse countries, socioeconomic backgrounds and minority groups. To boost motivation, it will include reminders, gamification features like badges and points, as well as personalized techniques such as action planning, problem solving, social reward, and positive self-talk.
  • Other: Control (generic advice) — The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. A 'light' version of the MELIORA VCI app will be developed to host the control group materials, track participants' step counts, send reminders, and allow scheduling of follow-up visits. No other features will be available in this version of the app.
Study Locations (7 sites)
Harokopio University, Athens, Greece
Lietuvos Sveikatos Mokslų Universitetas (Lsmu), Kaunas, Lithuania
Pagalbos Onkologiniams Ligoniams Asociacija (Pola L T), Kaunas, Lithuania
Fundación Para El Fomento de La Investigación Sanitaria Y Biomédica de La Comunitat Valenciana (Fisabio), Valencia, Spain
INCLIVA - Instituto de Investigación Sanitaria, Valencia, Spain
Bröstcancerföreningen Amazona I Stockholms Län (Amazona), Stockholm, Sweden
Karolinska Institutet, Stockholm, Sweden
Eligibility Criteria
Inclusion Criteria: MELIORA-HEALTHY study participants must meet all of the following criteria in order to be deemed eligible for study participation: * Reside in Greece, Lithuania, or Spain. * Be female and at least 18 years of age. * Have access to and be able to use a smartphone (iOS or Android) compatible with the MELIORA app. * Be willing and able to use the MELIORA app for the entire study duration. * Willing to provide informed consent to participate in the study. * Have at least one of the following behavioural or metabolic risk factors for BC, assessed in a random order (each site may determine the order that is most convenient for them) until eligibility is confirmed. If a risk factor is identified, the subsequent assessments can be skipped: * Increased alcohol consumption: More than 1 drink per day. * Increased body mass index (BMI): BMI ≥ 25 kg/m² or waist circumference ≥80 cm for normal weight individuals. * Physical inactivity: Not meeting World Health Organization (WHO) guidelines of at least 150 minutes of moderate-intensity or 75 minutes of high-intensity aerobic exercise per week during the last month. * Suboptimal diet: Low diet quality based on the rapid Prime Diet Quality Score Screener (rPDQS). MELIORA-PATIENTS study participants must meet all of the following criteria in order to be deemed eligible for study participation: * Reside in Spain or Lithuania. * Be female and at least 18 years old. * Have access to and be able to use a smartphone (iOS or Android) compatible with the MELIORA app. * Be willing and able to use the MELIORA app for the entire study duration. * Willing to provide informed consent to participate in the study. * Have been diagnosed with breast cancer (BC) within the last 6 months and/or currently undergoing treatment (chemotherapy, radiotherapy, immunotherapy, hormone therapy) and/or in active follow-up. * Have at least one of the following behavioural or metabolic risk factors for BC, assessed in a random order (each site may determine the order that is most convenient for them) until eligibility is confirmed. If a risk factor is identified, the subsequent assessments can be skipped: * Increased alcohol consumption: More than 1 drink per day. * Increased body mass index (BMI): BMI ≥ 25 kg/m² or waist circumference ≥80 cm for normal weight individuals. * Physical inactivity: Not meeting World Health Organization (WHO) guidelines of at least 150 minutes of moderate-intensity or 75 minutes of high-intensity aerobic exercise per week during the last month. * Suboptimal diet: Low diet quality based on the rapid Prime Diet Quality Score Screener (rPDQS). MELIORA-SURVIVORS study participants must meet all of the following criteria in order to be deemed eligible for study participation: * Reside in Spain, Lithuania, or Sweden. * Be female and at least 18 years old. * Have access to and be able to use a smartphone (iOS or Android) compatible with the MELIORA app. * Be willing and able to use the MELIORA app for the entire study duration. * Willing to provide informed consent to participate in the study. * Have completed primary treatment for breast cancer (surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, etc.) and currently be in remission. * Be considered "cancer-free" according to their treating physician and may enter the study immediately following this diagnosis. * Ongoing adjuvant hormone therapy is permitted. * Have at least one of the following behavioural or metabolic risk factors for BC, assessed in a random order (each site may determine the order that is most convenient for them) until eligibility is confirmed. If a risk factor is identified, the subsequent assessments can be skipped: * Increased alcohol consumption: More than 1 drink per day. * Increased body mass index (BMI): BMI ≥ 25 kg/m² or waist circumference ≥80 cm for normal weight individuals. * Physical inactivity: Not meeting World Health Organization (WHO) guidelines of at least 150 minutes of moderate-intensity or 75 minutes of high-intensity aerobic exercise per week during the past month. * Suboptimal diet: Low diet quality based on the rapid Prime Diet Quality Score Screener (rPDQS). Exclusion Criteria: MELIORA-HEALTHY study participants will be excluded from study participation if they meet any of the following criteria: * Inability to provide fully informed consent. * Inability to understand or communicate in the local language i.e. Greek in Greece, Lithuanian in Lithuania, Spanish in Spain. * Current or past diagnosis of cancer or other uncontrolled chronic diseases (e.g., cardiovascular disease, diabetes) that affect lifestyle, dietary habits, or communication skills. * Mental illness or disorders that affect lifestyle, dietary habits, or communication skills. * Use of medication that affects lifestyle, dietary habits, or communication skills. * Recreational drug use. * Pregnancy, lactation, or intention to become pregnant shortly before, during, or after the intervention. * Participation in another clinical trial or program aimed at promoting behavioural changes or weight loss at the time of recruitment. If subjects already use health-related apps that affect their weight and lifestyle, including dietary habits and physical activity, the research team will ask them to pause their use until the end of the 12-month study period. However, the use of these applications by the participants cannot be controlled. MELIORA PATIENTS and MELIORA SURVIVORS study participants will be excluded from study participation if they meet any of the following criteria: * Inability to provide fully informed consent. * Inability to understand or communicate in the local language (i.e., Lithuanian in Lithuania, Spanish in Spain, Swedish in Sweden), unless appropriate translation support is available to ensure full understanding of study procedures and informed consent. * Current or past diagnosis of cancer (other than breast cancer, except skin cancer treated with surgery only) or other uncontrolled chronic diseases (e.g., cardiovascular diseases, diabetes) that affect lifestyle, dietary habits, or communication skills. * Mental illness or disorders that affect lifestyle, dietary habits, and communication skills. * Use of medication that affects lifestyle, dietary habits, or communication skills. * Recreational drug use. * Pregnancy, lactation, or intention to become pregnant shortly before, during, or after the intervention. * Participation in another clinical trial or program to promote behavioural changes or weight loss during recruitment. Suppose participants are already using health-related apps affecting their weight and lifestyle, including dietary habits and physical activity. In that case, they will be asked to suspend their use until the end of the 12-month study period. However, the research team cannot control the use of these applications by the participants. * Severe adherence issues with previous treatments that may interfere with compliance with study tasks (subject to the investigator's assessment).
Conditions Type 2 Diabetes Mellitus (T2DM), Diabete...
Phase NA
Enrollment 1250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this project is to evaluate the effectiveness of diabetes distress screening and intervention on patients with type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: ARISE Learning Community Diabetes Distress Screening and Intervention — In-depth training for frontline community health center staff on ARISE algorithm to screen for degree of diabetes distress using T2-DDAS Core. If positive, screen for sources of diabetes distress using T2-DDAS Sources. Discuss results with patient and make any relevant referrals.
  • Behavioral: ARISE Enhanced Care brief training — Brief training on American Diabetes Association guidelines for screening for diabetes distress using the 7A's model

Primary Outcomes

  • Rate of A1C across time (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-10
Completion: 2028-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Chicago
Collaborators: University of California, San Francisco, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Midwest Clinicians' Network
Principal Investigators:
  • Arshiya Baig, MD, MPH (PRINCIPAL_INVESTIGATOR) - University of Chicago
  • Danielle Hessler Jones, PhD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Abby Sr. Research Project Manager, MSW
773-834-5646
abigail.durgan@bsd.uchicago.edu
Sr. Research Project Manager
773-834-5646
abigail.durgan@bsd.uchicago.edu
University of Chicago
Interventions
  • Behavioral: ARISE Learning Community Diabetes Distress Screening and Intervention — In-depth training for frontline community health center staff on ARISE algorithm to screen for degree of diabetes distress using T2-DDAS Core. If positive, screen for sources of diabetes distress using T2-DDAS Sources. Discuss results with patient and make any relevant referrals.
  • Behavioral: ARISE Enhanced Care brief training — Brief training on American Diabetes Association guidelines for screening for diabetes distress using the 7A's model
Study Locations (1 sites)
University of Chicago, Chicago, Illinois 60637 United States
Eligibility Criteria
Inclusion Criteria: * Patient at a participating clinic * Type 2 diabetes * Adult (18 years or older) * A1C \> 8% Exclusion Criteria: * Pregnant
Conditions Type 2 Diabetes, AI-supported Real-time ...
Phase NA
Enrollment 39
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

In Taiwan, an estimated 2.3 million individuals have diabetes, with a 44% increase observed among young adults and adolescents. Poor dietary habits and sedentary lifestyles are major risk factors for type 2 diabetes. The widespread use of smartphones has facilitated the development of digital health technologies, including digital food photography and artificial intelligence (AI), which show promise for personalized nutrition care and health promotion. While such technologies have demonstrated short-term success in diabetes management, their long-term effectiveness remains uncertain. This study aims to evaluate the effectiveness of a digital eHealth care intervention for individuals with diabetes. Participants will be recruited from the Diabetes Shared Care Network and community care centers in Taiwan and followed for 12 months. Eligible participants will be randomly assigned by computer to either a control or an eHealth care group. • eHealth Group: Receives a 10-minute digital nutrition education session using the lab-developed "3D/AR MetaFood food portion education platform" (https://sketchfab.com/susanlab108/collections) and is required to submit weekly dietary records through food images using the "Formosa FoodAPP." Participants will receive immediate dietary feedback from nutritionists, followed by AI-generated personalized feedback on the glycemic index (GI) and glycemic load (GL) of their meals. They will also be provided with educational videos on healthy eating, physical activity, and selecting low-GI/GL foods. Anthropometric measurements and baseline questionnaires will be collected at enrollment. Blood biochemistry, including HbA1c, will be measured at baseline, and at 3, 6, 9, and 12 months. Collected food image data will be used to train AI systems for real-time dietary feedback and to explore the relationship between nutrient intake and long-term glycemic control.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Real-Time Personalized Dietary Feedback (via AI and Nutritionist) — * Behavioral: "3D/AR MetaFood" Portion Size and Nutrition Education * Behavioral: Nutrition and Physical Activity Educational Videos
  • Behavioral: conventional nutrition education by dietitian — The participants receive conventional health and nutrition education from state registered dietitian.

Primary Outcomes

  • HbA1c (baseline, 3 month, 6 month, 9 month, 12 month)
  • Fasting glucose (baseline, 3 month, 6 month, 9 month, 12 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-19
Completion: 2025-10-01
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 39 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taipei Medical University
Principal Investigators:
  • Jung-Su Chang, PhD. (PRINCIPAL_INVESTIGATOR) - College of Nutrition, Taipei Medical University
Contact Information
Study Contact:
Jung-Su Chang, PhD.
886-66382736
susanchang@tmu.edu.tw
Jung-Su Chang, PhD
886-66382736
susanchang@tmu.edu.tw
Jung-Su Chang
Interventions
  • Behavioral: Real-Time Personalized Dietary Feedback (via AI and Nutritionist) — * Behavioral: "3D/AR MetaFood" Portion Size and Nutrition Education * Behavioral: Nutrition and Physical Activity Educational Videos
  • Behavioral: conventional nutrition education by dietitian — The participants receive conventional health and nutrition education from state registered dietitian.
Study Locations (1 sites)
Jung-Su Chang, Taipei, 110 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. 20 years old or older 2. Pre-diabetes or diabetes 3. Taiwan nationality or fluent in Mandarin or Taiwanese 4. Not pregnant or breastfeeding 5. Capable (or assisted by a caregiver) of using a smartphone to photograph and record meals Exclusion Criteria: 1. Eating disorders 2. Undergoing treatment for severe illnesses that could affect normal dietary intake (e.g., cancer) 3. Unable to use a smartphone to take photos and record food intake.